S. Nassir Ghaemi, MD, MPH

  • 27Articles
  • 92.9KReads
  • 1998–2025Active
  • 78Collaborators
  • 2.7KCitations

About

S. Nassir Ghaemi, MD, MPH, is affiliated with Novartis Biomedical Research in Cambridge, Massachusetts, Tufts University School of Medicine, and Harvard Medical School in Boston, Massachusetts. Ghaemi has contributed 27 articles to Psychiatrist.com between 1998 and 2025, focusing on topics such as bipolar disorder, depression, mood disorders, psychopharmacology, addiction, neurodevelopmental conditions, and psychiatry. Frequent co-authors include Gary S. Sachs, Frederick K. Goodwin, Joseph F. Goldberg, Michael E. Thase, and Benjamin Zablotsky.

Publications

JCP
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
Original Research

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
, , , et al
JCP
Letter to the Editor

Antidepressants Added Nothing to Mood Stabilizers Alone: Reply to Terao

June 22, 2021

Dr Ghaemi responds to Dr Terao’s letter regarding a study of citalopram for bipolar depression.
JCP
Original Research

Efficacy of Citalopram Treatment in Bipolar Depression

January 12, 2021

Antidepressants are widely used to treat bipolar illness, though their effectiveness in this disorder has not been established. This randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of...
, , , et al
JCP
In Memoriam

In Memoriam: Frederick K. Goodwin, MD

October 13, 2020

S. Nassir Ghaemi reflects on the life and accomplishments of this founding pioneer of psychopharmacology.
JCP
ASCP Corner

Existential Psychopharmacologic Clinical Practice: A Humanistic Approach to the "Med Check"

April 24, 2018

Psychopharmacotherapy is often shoehorned into a 15-minute session, or "med check," that inhibits the therapeutic alliance and frustrates both patients and clinicians. This ASCP Corner article delineates an "existential...
, ,
PCC
Letter to the Editor

Treatment Strategies for Bipolar Disorder: CALM SEA

May 19, 2011

,
JCP
Letter to the Editor

Reply to Do Antidepressants Really Beget More Depressive Episodes?

January 15, 2011

JCP
Original Research

Antidepressant Discontinuation in Bipolar Depression: A Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Randomized Clinical Trial of Long-Term Effectiveness and Safety

April 15, 2010

, , , et al
JCP
Letter to the Editor

Reliability, Not Overdiagnosis

May 14, 2009

JCP
Original Research

Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder: Findings From the STEP-BD

February 10, 2009

, , , et al
PCC
Letter to the Editor

CALM: A Mnemonic for Treatment Options for Bipolar Disorder

December 15, 2008

,
JCP
Letter to the Editor

Is Aripiprazole an Efficacious Adjunct for Unipolar Depression?

June 30, 2008

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe